Regenxbio (RGNX) Shares Surge 37% on FDA Reversal Decision

The Quick Take

• Regenxbio (RGNX) shares jumped 37% following a positive FDA reversal on a gene therapy decision
• The FDA reversal marks a significant regulatory catalyst for Regenxbio gene therapy pipeline recovery
• RGNX joins a wave of FDA-driven biotech re-ratings in 2026 as the agency recalibrates gene therapy standards

Regenxbio Inc., a clinical-stage gene therapy company listed on NASDAQ under ticker RGNX, saw its shares surge approximately 37% following reports of an FDA reversal decision on a gene therapy-related regulatory ruling. Gene therapy companies face binary regulatory risk: a single FDA decision — approval, rejection, or a reversal of a prior position — can produce outsized single-session moves as investors reprice the probability-weighted value of the entire pipeline. The 37% move confirms that RGNX was trading at a significant discount to its base scenario prior to the reversal, indicating the market had heavily weighted an adverse outcome.

For the gene therapy sector broadly, FDA reversal decisions carry important read-across implications. Regenxbio specialises in adeno-associated virus (AAV) vector delivery platforms — a technology that underpins multiple approved and pipeline gene therapies across rare and common disease indications. A positive FDA reversal at RGNX may signal broader regulatory receptivity toward AAV-based gene therapies, which had faced scrutiny after early 2024-2025 adverse events in some clinical trials. Peers including Sarepta Therapeutics, uniQure, and Spark Therapeutics — all operating in overlapping AAV gene therapy spaces — may see secondary sentiment lift.

The most important forward signal is the specific detail of what FDA reversed — whether it was a clinical hold, a complete response letter, or a broader policy position on the technology — as this determines how durable the RGNX recovery is. Watch for the company data release or investor update that follows an FDA reversal, which typically produces a further trading catalyst as clinical specifics are disclosed. The macro variable is the FDA gene therapy policy environment under current leadership, which ultimately determines the pace and severity of the remaining regulatory risk in the sector.

Synthesized from 1 source.